by Jordana Choucair | Apr 14, 2022 | Opioid/Substance Use Disorders
A new congressional report found that more than 20 employees from consulting firm McKinsey worked for the U.S. government on issues related to the opioid epidemic while also doing the same type of consulting for major opioid makers like Purdue Pharma. The report...
by Jordana Choucair | Apr 13, 2022 | Opioid/Substance Use Disorders
Eleanor Health, an addiction and mental health care provider, has secured $50 million in a series C funding round led by General Catalyst. The startup’s evidence-based care model offers a variety of addiction and mental health services with a tech platform that allows...
by Jordana Choucair | Apr 12, 2022 | Opioid/Substance Use Disorders
Forge Health, a company that provides both in-person and digital mental health and substance use treatment, secured $11 million in new financing to build out its tech capabilities and expand its value-based partnerships. The company plans to use the funding to expand...
by Jordana Choucair | Apr 11, 2022 | Opioid/Substance Use Disorders
The Centers for Disease Control and Prevention (CDC) is expected to release updated guidelines regarding opioid prescribing practices. The proposed guidelines include some notable changes: they no longer include specific limits on the dose and duration of an opioid...
by Jordana Choucair | Mar 31, 2022 | Opioid/Substance Use Disorders
Just ahead of a trial, the state of Florida reached a settlement with three major companies over their roles in the opioid crisis. Under the agreement, CVS Health Corp. will pay $484 million, Allergan PLC will pay $134 million, and Teva Pharmaceuticals Industries Ltd....
by Jordana Choucair | Mar 22, 2022 | Opioid/Substance Use Disorders
Allergan and Teva Pharmaceutical reached a $107 million settlement with the state of Rhode Island over their alleged roles in fomenting the U.S. opioid crisis. Under the deal, Teva will pay $21.5 million over 13 years and supply the state with two medicines to combat...
Recent Comments